医学
代谢综合征
肥胖
儿科
国家胆固醇教育计划
儿童肥胖
糖尿病
超重
体质指数
梅德林
人口
系统回顾
内科学
作者
Amanda Jane Friend,LCA Craig,SW Turner
标识
DOI:10.1136/archdischild-2012-301885.277
摘要
497 Objectives Zr-89 (t1/2= 3.17 days) has been produced and isolated to prepare Zr-89-radiolabeled monoclonal antibodies (mAbs) for use as immunoPET agents. The work presented describes the preparation of Zr-89-DFO-Herceptin for delineating HER2-positive tumors for imaging of breast cancer in vivo. Methods Zr-89 has been produced via the Y-89(p,n)Zr-89 transmutation with high radiochemical yields (ave. 1.53 mCi/μAh) and was isolated quantitatively from the naturally abundant Y-89 solid target by use of a hydroxamate functionalized resin. Herceptin was conjugated to the chelate DFO by use of three different linker groups and the modified DFO-Herceptin was radiolabeled with Zr-89 with >95% RCP. In vitro studies including ligand challenge experiments, pH studies and immunoreactivity assays were used to examine the stability and viability of the Zr-89-DFO-Herceptin samples. Small animal PET imaging and biodistribution studies used to characterize the ability of Zr-89-DFO-Herceptin to delineate HER2-positive tumors in vivo will be presented. Results Radiolabeling of DFO-Herceptin proceeded in high radiochemical yield with high chemical and radionuclidic purity (>99%). In vitro assays showed that the stability of the Zr-89-DFO-mAb conjugate is dependent on the choice of linker and the method of functionalization affects the immunoreactivity, with typical values between 0.8 – 0.9. Preliminary in vivo studies show uptake in HER2 positive tumors with good image resolution. Conclusions The results indicate that Zr-89-DFO-Herceptin remains structurally viable and is stable with respect to mAb degradation and loss of Zr-89. The in vivo data demonstrate that Zr-89 is a very promising radionuclide for application in immunoPET agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI